# Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia

> **NCT02079844** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 20 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Roflumilast
- **DRUG:** Placebo
- **DRUG:** Second generation antipsychotic

## Key facts

- **NCT ID:** NCT02079844
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02079844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02079844, "Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02079844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*